

David Cuthbertson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4208467/publications.pdf>

Version: 2024-02-01

90
papers

3,116
citations

159585

30
h-index

168389

53
g-index

94
all docs

94
docs citations

94
times ranked

3430
citing authors

#	ARTICLE	IF	CITATIONS
1	HOMA2-B enhances assessment of type 1 diabetes risk among TrialNet Pathway to Prevention participants. <i>Diabetologia</i> , 2022, 65, 88-100.	6.3	2
2	Hypothyroidism in vasculitis. <i>Rheumatology</i> , 2022, 61, 2942-2950.	1.9	2
3	Telomere length is not a main factor for the development of islet autoimmunity and type 1 diabetes in the TEDDY study. <i>Scientific Reports</i> , 2022, 12, 4516.	3.3	6
4	Self-Reported Data and Physician-Reported Data in Patients With Eosinophilic Granulomatosis With Polyangiitis: Comparative Analysis. <i>Interactive Journal of Medical Research</i> , 2022, 11, e27273.	1.4	2
5	Characterization of Severity in Zellweger Spectrum Disorder by Clinical Findings: A Scoping Review, Meta-Analysis and Medical Chart Review. <i>Cells</i> , 2022, 11, 1891.	4.1	8
6	Sequence-Based Screening of Patients With Idiopathic Polyarteritis Nodosa, Granulomatosis With Polyangiitis, and Microscopic Polyangiitis for Deleterious Genetic Variants in <i>ADA2</i> . <i>Arthritis and Rheumatology</i> , 2021, 73, 512-519.	5.6	34
7	Association between family history, early growth and the risk of beta cell autoimmunity in children at risk for type 1 diabetes. <i>Diabetologia</i> , 2021, 64, 119-128.	6.3	12
8	Growth and development of islet autoimmunity and type 1 diabetes in children genetically at risk. <i>Diabetologia</i> , 2021, 64, 826-835.	6.3	18
9	Serum fatty acids and risk of developing islet autoimmunity: A nested case-control study within the TRIGR birth cohort. <i>Pediatric Diabetes</i> , 2021, 22, 577-585.	2.9	10
10	Health-related quality of life in adults with osteogenesis imperfecta. <i>Clinical Genetics</i> , 2021, 99, 772-779.	2.0	4
11	Clinical Manifestations and Long-Term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America. <i>ACR Open Rheumatology</i> , 2021, 3, 404-412.	2.1	21
12	Diabetic Ketoacidosis at the Time of Diagnosis of Type 1 Diabetes in Children. <i>JAMA Pediatrics</i> , 2021, 175, 518.	6.2	3
13	Dietary compliance in a randomized double-blind infant feeding trial during infancy aiming at prevention of type 1 diabetes. <i>Food Science and Nutrition</i> , 2021, 9, 4221-4231.	3.4	0
14	<i>TCF7L2</i> Genetic Variants Do Not Influence Insulin Sensitivity or Secretion Indices in Autoantibody-Positive Individuals at Risk for Type 1 Diabetes. <i>Diabetes Care</i> , 2021, 44, 2039-2044.	8.6	0
15	Pregnancy in women with osteogenesis imperfecta: pregnancy characteristics, maternal, and neonatal outcomes. <i>American Journal of Obstetrics & Gynecology MFM</i> , 2021, 3, 100362.	2.6	11
16	Increasing plasma glucose before the development of type 1 diabetes—the TRIGR study. <i>Pediatric Diabetes</i> , 2021, 22, 974-981.	2.9	6
17	The Deterrence of Rapid Metabolic Decline Within 3 Months After Teplizumab Treatment in Individuals at High Risk for Type 1 Diabetes. <i>Diabetes</i> , 2021, 70, 2922-2931.	0.6	11
18	Effect of extensively hydrolyzed casein vs. conventional formula on the risk of asthma and allergies: The TRIGR randomized clinical trial. <i>Pediatric Allergy and Immunology</i> , 2021, 32, 670-678.	2.6	5

#	ARTICLE	IF	CITATIONS
19	Efficacy of leflunomide in the treatment of vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 114-118.	0.8	14
20	Urinary soluble CD163 and monocyte chemoattractant protein-1 in the identification of subtle renal flare in anti-neutrophil cytoplasmic antibody-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 283-291.	0.7	40
21	Derivation of an angiographically based classification system in Takayasu's arteritis: an observational study from India and North America. <i>Rheumatology</i> , 2020, 59, 1118-1127.	1.9	33
22	Evaluation of Potential Serum Biomarkers of Disease Activity in Diverse Forms of Vasculitis. <i>Journal of Rheumatology</i> , 2020, 47, 1001-1010.	2.0	20
23	Patterns of Arterial Disease in Takayasu Arteritis and Giant Cell Arteritis. <i>Arthritis Care and Research</i> , 2020, 72, 1615-1624.	3.4	77
24	Serum 25-hydroxyvitamin D concentration in childhood and risk of islet autoimmunity and type 1 diabetes: the TRIGR nested case-control ancillary study. <i>Diabetologia</i> , 2020, 63, 780-787.	6.3	28
25	Hearing loss in individuals with osteogenesis imperfecta in North America: Results from a multicenter study. <i>American Journal of Medical Genetics, Part A</i> , 2020, 182, 697-704.	1.2	17
26	Pediatric Outcomes Data Collection Instrument is a Useful Patient-Reported Outcome Measure for Physical Function in Children with Osteogenesis Imperfecta. <i>Genetics in Medicine</i> , 2020, 22, 581-589.	2.4	14
27	A combined risk score enhances prediction of type 1 diabetes among susceptible children. <i>Nature Medicine</i> , 2020, 26, 1247-1255.	30.7	83
28	Distinct Growth Phases in Early Life Associated With the Risk of Type 1 Diabetes: The TEDDY Study. <i>Diabetes Care</i> , 2020, 43, 556-562.	8.6	28
29	Association of diabetes-related autoantibodies with the incidence of asthma, eczema and allergic rhinitis in the TRIGR randomised clinical trial. <i>Diabetologia</i> , 2020, 63, 1796-1807.	6.3	8
30	Patterns of clinical presentation in Takayasu's arteritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 576-581.	3.4	25
31	Growth characteristics in individuals with osteogenesis imperfecta in North America: results from a multicenter study. <i>Genetics in Medicine</i> , 2019, 21, 275-283.	2.4	34
32	Arterial lesions in giant cell arteritis: A longitudinal study. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 707-713.	3.4	43
33	A Multicenter Observational Cohort Study to Evaluate the Effects of Bisphosphonate Exposure on Bone Mineral Density and Other Health Outcomes in Osteogenesis Imperfecta. <i>JBMR Plus</i> , 2019, 3, e10118.	2.7	22
34	Subglottic stenosis and endobronchial disease in granulomatosis with polyangiitis. <i>Rheumatology</i> , 2019, 58, 2203-2211.	1.9	37
35	148. SHORT-FORM 36 AS A MEASURE OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH GIANT CELL ARTERITIS. <i>Rheumatology</i> , 2019, 58, .	1.9	0
36	145. EVALUATION OF NOVEL SERUM BIOMARKERS OF DISEASE ACTIVITY IN GIANT CELL ARTERITIS, TAKAYASU'S ARTERITIS, POLYARTERITIS NODOSA, AND EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS. <i>Rheumatology</i> , 2019, 58, .	1.9	0

#	ARTICLE	IF	CITATIONS
37	020.â€fIDENTIFICATION OF TARGET ANTIGENS FOR ANTI-ENDOTHELIAL CELL ANTIBODIES IN PATIENTS WITH TAKAYASUâ€™S ARTERITIS USING PROTEOMICS. <i>Rheumatology</i> , 2019, 58, .	1.9	0
38	043.â€fSUBGLOTTIC STENOSIS AND ENDOBRONCHIAL DISEASE IN GRANULOMATOSIS WITH POLYANGIITIS. <i>Rheumatology</i> , 2019, 58, .	1.9	0
39	035.â€fCANDIDATE BIOMARKERS IN ANCA-ASSOCIATED VASCULITIS IDENTIFIED USING A PROTEOMIC APPROACH. <i>Rheumatology</i> , 2019, 58, .	1.9	0
40	084.â€fDISCOVERY AND VALIDATION OF A NOVEL ANGIOGRAPHIC CLASSIFICATION SCHEME IN TAKAYASUâ€™S ARTERITIS. <i>Rheumatology</i> , 2019, 58, .	1.9	0
41	138.â€fDIFFUSE ALVEOLAR HEMORRHAGE, PULMONARY NODULES AND INFILTRATES IN GRANULOMATOSIS POLYANGIITIS AND MICROSCOPIC POLYANGIITIS. A COHORT STUDY OF 736 PATIENTS. <i>Rheumatology</i> , 2019, 58, .	1.9	0
42	083.â€fCOMPARISON OF ARTERIAL PATTERNS OF DISEASE IN TAKAYASUâ€™S ARTERITIS AND GIANT CELL ARTERITIS. <i>Rheumatology</i> , 2019, 58, .	1.9	3
43	Feasibility and Construct Validation of the Patient Reported Outcomes Measurement Information System in Systemic Vasculitis. <i>Journal of Rheumatology</i> , 2019, 46, 928-934.	2.0	6
44	Mobility in osteogenesis imperfecta: a multicenter North American study. <i>Genetics in Medicine</i> , 2019, 21, 2311-2318.	2.4	15
45	Predicting Islet Cell Autoimmunity and Type 1 Diabetes: An 8-Year TEDDY Study Progress Report. <i>Diabetes Care</i> , 2019, 42, 1051-1060.	8.6	75
46	Serum S100 Proteins as a Marker of Disease Activity in Large Vessel Vasculitis. <i>Journal of Clinical Rheumatology</i> , 2018, 24, 393-395.	0.9	16
47	Evaluation of damage in giant cell arteritis. <i>Rheumatology</i> , 2018, 57, 322-328.	1.9	28
48	Biochemical markers and neuropsychological functioning in distal urea cycle disorders. <i>Journal of Inherited Metabolic Disease</i> , 2018, 41, 657-667.	3.6	31
49	Safety and efficacy of autoantigenâ€™specific therapy with 2 doses of alumâ€™formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for type 1 diabetes: A randomized clinical trial. <i>Pediatric Diabetes</i> , 2018, 19, 410-419.	2.9	45
50	Serum periostin as a biomarker in eosinophilic granulomatosis with polyangiitis. <i>PLoS ONE</i> , 2018, 13, e0205768.	2.5	6
51	A multicenter study to evaluate pulmonary function in osteogenesis imperfecta. <i>Clinical Genetics</i> , 2018, 94, 502-511.	2.0	33
52	A Randomized, Doubleâ€™Blind Trial of Abatacept (CTLAâ€™4Ig) for the Treatment of Takayasu Arteritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 846-853.	5.6	131
53	A Randomized, Doubleâ€™Blind Trial of Abatacept (CTLAâ€™4Ig) for the Treatment of Giant Cell Arteritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 837-845.	5.6	271
54	Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibodyâ€™Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2017, 69, 1054-1066.	5.6	130

#	ARTICLE	IF	CITATIONS
55	Regional differences in milk and complementary feeding patterns in infants participating in an international nutritional type 1 diabetes prevention trial. <i>Maternal and Child Nutrition</i> , 2017, 13, .	3.0	15
56	OMERACT Endorsement of Patient-reported Outcome Instruments in Antineutrophil Cytoplasmic Antibody-associated Vasculitis. <i>Journal of Rheumatology</i> , 2017, 44, 1529-1535.	2.0	25
57	The Birmingham Vasculitis Activity Score as a Measure of Disease Activity in Patients with Giant Cell Arteritis. <i>Journal of Rheumatology</i> , 2016, 43, 1078-1084.	2.0	37
58	Vasculitis in patients with inflammatory bowel diseases: A study of 32 patients and systematic review of the literature. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 475-482.	3.4	109
59	Serum Biomarkers in Patients with Relapsing Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss). <i>PLoS ONE</i> , 2015, 10, e0121737.	2.5	35
60	Identification of Susceptibility Loci in <i>IL6</i> , <i>RPS9</i> , and <i>LILRB3</i> , and an Intergenic Locus on Chromosome 21q22 in Takayasu Arteritis in a Genome-Wide Association Study. <i>Arthritis and Rheumatology</i> , 2015, 67, 1361-1368.	5.6	79
61	The Effect of DPT-1 Intravenous Insulin Infusion and Daily Subcutaneous Insulin on Endogenous Insulin Secretion and Postprandial Glucose Tolerance. <i>Diabetes Care</i> , 2015, 38, 891-896.	8.6	8
62	Disease Relapses among Patients with Giant Cell Arteritis: A Prospective, Longitudinal Cohort Study. <i>Journal of Rheumatology</i> , 2015, 42, 1213-1217.	2.0	129
63	Cardiac Involvement in Granulomatosis with Polyangiitis. <i>Journal of Rheumatology</i> , 2015, 42, 1209-1212.	2.0	87
64	First test effect in intravenous glucose tolerance testing. <i>Pediatric Diabetes</i> , 2015, 16, 129-137.	2.9	1
65	Value of commonly measured laboratory tests as biomarkers of disease activity and predictors of relapse in eosinophilic granulomatosis with polyangiitis. <i>Rheumatology</i> , 2015, 54, 1351-1359.	1.9	52
66	Large-Scale Prospective T Cell Function Assays in Shipped, Unfrozen Blood Samples: Experiences from the Multicenter TRIGR Trial. <i>Vaccine Journal</i> , 2014, 21, 203-211.	3.1	2
67	Distribution of C-Peptide and Its Determinants in North American Children at Risk for Type 1 Diabetes. <i>Diabetes Care</i> , 2014, 37, 1959-1965.	8.6	6
68	Use of vitamin D supplements during infancy in an international feeding trial. <i>Public Health Nutrition</i> , 2014, 17, 810-822.	2.2	8
69	Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPtrs) for Improving the Accuracy of the Risk Classification of Type 1 Diabetes. <i>Diabetes Care</i> , 2014, 37, 979-984.	8.6	37
70	An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's). <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1376-1379.	0.9	128
71	Clinical characteristics of patients with spinocerebellar ataxias 1, 2, 3 and 6 in the US; a prospective observational study. <i>Orphanet Journal of Rare Diseases</i> , 2013, 8, 177.	2.7	117
72	An overview of the rare diseases clinical research network. <i>Molecular Genetics and Metabolism</i> , 2013, 108, S59.	1.1	0

#	ARTICLE	IF	CITATIONS
73	New Features of Disease After Diagnosis in 6 Forms of Systemic Vasculitis. <i>Journal of Rheumatology</i> , 2013, 40, 1905-1912.	2.0	40
74	Urinary Biomarkers in Relapsing Antineutrophil Cytoplasmic Antibody-associated Vasculitis. <i>Journal of Rheumatology</i> , 2013, 40, 674-683.	2.0	39
75	Performance of HbA1c as an Early Diagnostic Indicator of Type 1 Diabetes in Children and Youth. <i>Diabetes Care</i> , 2012, 35, 1821-1825.	8.6	39
76	Distribution of arterial lesions in Takayasu's arteritis and giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1329-1334.	0.9	218
77	The Application of the Diabetes Prevention Trial—Type 1 Risk Score for Identifying a Preclinical State of Type 1 Diabetes. <i>Diabetes Care</i> , 2012, 35, 1552-1555.	8.6	33
78	Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. <i>Blood</i> , 2012, 120, 4945-4951.	1.4	126
79	Prognostic Accuracy of Immunologic and Metabolic Markers for Type 1 Diabetes in a High-Risk Population. <i>Diabetes Care</i> , 2012, 35, 1975-1980.	8.6	34
80	Seroreactivity to LGL leukemia-specific epitopes in aplastic anemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria: Results of a bone marrow failure consortium study. <i>Leukemia Research</i> , 2012, 36, 581-587.	0.8	13
81	Growth differences between North American and European children at risk for type 1 diabetes. <i>Pediatric Diabetes</i> , 2012, 13, 425-431.	2.9	3
82	A comparison of the baseline metabolic profiles between Diabetes Prevention Trial-Type 1 and TrialNet Natural History Study participants. <i>Pediatric Diabetes</i> , 2011, 12, 85-90.	2.9	12
83	Final Results From the Phase 2 Continuation Study of the Lenalidomide and Azacitidine Combination in Patients with Higher-Risk Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2011, 118, 607-607.	1.4	1
84	Breastfeeding patterns of mothers with type 1 diabetes: results from an infant feeding trial. <i>Diabetes/Metabolism Research and Reviews</i> , 2010, 26, 206-211.	4.0	50
85	HTLV-1 Epitope (BA21) Reactivity in Rare Bone Marrow Failure Diseases. <i>Blood</i> , 2010, 116, 1724-1724.	1.4	0
86	Incident Dysglycemia and Progression to Type 1 Diabetes Among Participants in the Diabetes Prevention Trial—Type 1. <i>Diabetes Care</i> , 2009, 32, 1603-1607.	8.6	59
87	Final Results from a Phase I Combination Study of Lenalidomide and Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2008, 112, 221-221.	1.4	11
88	Role of Insulin Resistance in Predicting Progression to Type 1 Diabetes. <i>Diabetes Care</i> , 2007, 30, 2314-2320.	8.6	94
89	Elevated Fas Ligand and BA21 Serorecognition as Disease Correlates in Bone Marrow Failure Disorders: Taking Advantage of the LGL Leukemia Model. <i>Blood</i> , 2007, 110, 4274-4274.	1.4	0
90	Web-based surveys using Patient-Reported Outcome Measurement Information System (PROMIS) instruments allow documentation of important components of the disease experience among individuals with Osteogenesis Imperfecta. <i>Bone Abstracts</i> , 0, , .	0.0	0